Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laquinimod SCHEMBL12009998 | 0.96 | MEN1 (0.42) | MEN1KMT2APGREGFRTP53 | |
| Laquinimod SCHEMBL889486 | 0.95 | MEN1 (0.46) | MEN1KMT2APGREGFRTP53 | |
| Laquinimod SCHEMBL12009979 | 0.91 | TP53 (0.48) | MEN1KMT2APGREGFRTP53 | |
| Laquinimod SCHEMBL889478 | 0.91 | MEN1 (0.47) | MEN1KMT2APGREGFRTP53 | |
| SCHEMBL16248354 | 0.88 | HDAC4 (0.41) | MEN1KMT2APGREGFRHDAC4 | |
| Laquinimod SCHEMBL12009995 | 0.87 | MEN1 (0.36) | MEN1KMT2APGRTP53NPC1 | |
| SCHEMBL889412 | 0.85 | KMT2A (0.40) | MEN1KMT2APGREGFRHDAC4 | |
| Laquinimod SCHEMBL889446 | 0.84 | HDAC4 (0.38) | MEN1KMT2APGREGFRHDAC4 | |
| Laquinimod SCHEMBL39440 | 0.84 | TP53 (0.50) | MEN1KMT2APGREGFRTP53 | |
| Laquinimod SCHEMBL29438575 | 0.84 | TP53 (0.50) | MEN1KMT2APGREGFRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252933-B2 | 2-oxo-1,2-dihydro-quinoline modulators of immune function | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2012-08-28 | — | — | US | disclosed |
| US-20100055072-A1 | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055072-A1 | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION | IFNG, IRF3, IL2 | MEN1 4304/4885KMT2A 1505/4885PGR 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.